{
  "id": "adv_mhgap#referral_727d7366",
  "content": "The widespread use of mhGAP has important\nof WHO recommendations was published in 2010\nimplications, from direct clinical care to policy and\nas part of the mhGAP intervention guide (2,6). The\nsystem-wide changes. The use of mhGAP also affects\nrecommendations were updated and published in the\nother health systems strengthening efforts – for\n2015 mhGAP guideline (7,8), followed a year later by the\nexample, it has had an influence on the WHO model list\nupdated intervention guide in 2016 (9). These evidence-\nof essential medicines (known as the EML) (13).\n2\n1. Introduction\n1.2 Aims and objectives The guideline is relevant to other health-care\nprofessionals globally, including staff at ministries of\nThis mhGAP guideline aims to: health, international and national nongovernmental\n▶ provide up-to-date WHO guidance to facilitate organizations (NGOs), and researchers at academic\ndelivery of MNS interventions by non-specialist institutions, especially in LMICs.\nhealth workers in LMICs;\nIt is also intended for use by health-care planners\n▶ assist with the scale-up of care for MNS disorders\nand programme managers in close conceptual and\nidentified as conditions of high priority in LMICs; and\nstrategic synergy with the four WHO action plans\n▶ facilitate implementation of WHO action plans",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "work",
      "referral"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Referral The widespread use of mhGAP has important\nof WHO recommendations was published in 2010\nimplications, from direct clinical care to policy and\nas part of the mhGAP intervention guide (2,6). The\nsystem-wide changes. The use of mhGAP also affects\nrecommendations were updated and published in the\nother health systems strengthening efforts – for\n2015 mhGAP guideline (7,8), followed a year later by the\nexample, it has had an influence on the WHO model list\nupdated intervention guide in 2016 (9). These evidence-\nof essential medicines (known as the EML) (13).\n2\n1. Introduction\n1.2 Aims and objectives The guideline is relevant to other health-care\nprofessionals globally, including staff at ministries of\nThis mhGAP guideline aims to: health, international and national nongovernmental\n▶ provide up-to-date WHO guidance to facilitate organizations (NGOs), and researchers at academic\ndelivery of MNS interventions by non-specialist institutions, especially in LMICs.\nhealth workers in LMICs;\nIt is also intended for use by health-care planners\n▶ assist with the scale-up of care for MNS disorders\nand programme managers in close conceptual and\nidentified as conditions of high priority in LMICs; and\nstrategic synergy with the four WHO action plans\n▶ facilitate implementation of WHO action plans The widespread use of mhgap has important\nof who recommendations was published in 2010\nimplications, from direct clinical care to policy and\nas part of the mhgap intervention guide (2,6). the\nsystem-wide changes."
}